Track the Ayala Pharmaceuticals, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Health Care sector, Ayala Pharmaceuticals, Inc. has published 8 insider filings. Market capitalisation: €1,096.4bn. The latest transaction was filed on 12 February 2024 (Levée d'options). Among the most active insiders: Israel Biotech Fund I, L.P.. The full history is openly available.
8
Insider Decl.
n/a
Thresholds
n/a
2 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Ayala Pharmaceuticals, Inc. Strong Buy (bullish), based on 42 analysts. Average price target: US$1,491.95.
23Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 3,817 of 28,803 companies
71.3
score / 100
Value
64
Quality
79
FCF yld1.2%
Earn yld6.4%
EV/EBITDA8.1x
ROE67%
Gross mgn40%
Net mgn23%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Ayala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for rare cancers and genetic diseases. It is listed on NASDAQ under the symbol AYLA.